MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4244/eij-d-25-00031

Медицинская библиотека · EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025

Transcatheter mitral repair in patients with symptomatic moderate functional mitral regurgitation: 1-year outcomes from the MiCLASP study.

Lurz Philipp, Rudolph Volker, Rassaf Tienush, Luedike Peter, Schmitz Thomas, Kister Tobias, Geisler Tobias, Lubos Edith, Eitel Ingo, von Bardeleben Ralph Stephan, Brambilla Nedy, Berti Sergio, Linke Axel, Unsöld Bernhard, Hengstenberg Christian, Baldus Stephan, Spargias Konstantinos, Nickenig Georg, Denti Paolo, Möllmann Helge, Rottbauer Wolfgang, Praz Fabien, Butter Christian, Reinthaler Markus, Van Mieghem Nicolas M, Edelmann Frank, Swaans Martin J, Witkowski Adam, Buch Mamta H, Seidler Tim, Iñiguez Andrés, Marcoff Leo, Koulogiannis Konstantinos, Hausleiter Jörg, Of The MiCLASP Study Investigators On Behalf

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Current clinical guidelines do not recommend mitral transcatheter edge-to-edge repair (M-TEER) for patients with moderate functional mitral regurgitation (FMR), and the implications of M-TEER in this population are not well documented.

AIMS: We aimed to assess M-TEER outcomes in patients with symptomatic moderate FMR compared to those with FMR ≥3+ who were treated with the PASCAL system in the MiCLASP study.

METHODS

Patients were stratified by baseline FMR grade (2+ or ≥3+). The echocardiographic core laboratory-assessed mitral regurgitation (MR) reduction, clinical events committee-adjudicated major adverse events (MAE) rate and functional and quality-of-life outcomes were evaluated up to 1 year after M-TEER.

RESULTS

Of the 544 (FMR=322; degenerative MR=163; mixed/other=59) enrolled patients, 101 had baseline FMR 2+ and 197 FMR ≥3+. Both groups achieved significant MR reduction at discharge, which was sustained up to 1 year, with 89.8% of patients achieving MR ≤1+ in the FMR 2+ group and 77.8% in the FMR ≥3+ group (all p<0.001 vs baseline). At 1 year, significant improvements (all p<0.001 vs baseline) in functional capacity (New York Heart Association Class I/II: 67.1% FMR 2+; 70.1% FMR ≥3+) and quality of life (change in the Kansas City Cardiomyopathy Questionnaire overall score: +13.9 points FMR 2+; +13.9 points FMR ≥3+) were achieved in both groups, with high survival (90.0% FMR 2+; 84.2% FMR ≥3+; p=0.176) and low MAE rates (13.9% FMR 2+; 18.3% FMR ≥3+; p=0.413).

CONCLUSIONS

In the MiCLASP study, patients with moderate FMR experienced significant MR reduction at 1 year, resulting in clinical and symptomatic benefits comparable to those with ≥moderate-severe FMR, suggesting that select patients with symptomatic moderate FMR can benefit from M-TEER.

Для цитирования: Lurz Philipp, Rudolph Volker, Rassaf Tienush, Luedike Peter, Schmitz Thomas, Kister Tobias, Geisler Tobias, Lubos Edith, Eitel Ingo, von Bardeleben Ralph Stephan, Brambilla Nedy, Berti Sergio, Linke Axel, Unsöld Bernhard, Hengstenberg Christian, Baldus Stephan, Spargias Konstantinos, Nickenig Georg, Denti Paolo, Möllmann Helge, Rottbauer Wolfgang, Praz Fabien, Butter Christian, Reinthaler Markus, Van Mieghem Nicolas M, Edelmann Frank, Swaans Martin J, Witkowski Adam, Buch Mamta H, Seidler Tim, Iñiguez Andrés, Marcoff Leo, Koulogiannis Konstantinos, Hausleiter Jörg, Of The MiCLASP Study Investigators On Behalf. Transcatheter mitral repair in patients with symptomatic moderate functional mitral regurgitation: 1-year outcomes from the MiCLASP study.. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2025. DOI: 10.4244/eij-d-25-00031.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.